Details

Autor(en) / Beteiligte

• DARRINGTON, D. L
• VOSE, J. M
• WEISENBURGER, D. D
• KESSINGER, A
• ARMITAGE, J. O
• ANDERSON, J. R
• BIERMAN, P. J
• BISHOP, M. R
• CHAN, W. C
• MORRIS, M. E
• REED, E. C
• SANGER, W. G
• TARANTOLO, S. R

Titel

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

Ist Teil von

• Journal of clinical oncology, 1994-12, Vol.12 (12), p.2527-2534

Ort / Verlag

Baltimore, MD: American Society of Clinical Oncology

Erscheinungsjahr

1994

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS). Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken. Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL. There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.